Comparison of IVIg and PLEX in patients with myasthenia gravis
Top Cited Papers
- 7 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 76 (23), 2017-2023
- https://doi.org/10.1212/wnl.0b013e31821e5505
Abstract
Objective: Both IV immunoglobulin (IVIg) and plasma exchange (PLEX) are immunomodulatory treatments used to treat patients with myasthenia gravis (MG), but the choice of which treatment to administer to patients is limited due to lack of evidence from adequately powered, masked, randomized, standardized trials. Methods: We randomized 84 patients with moderate to severe MG defined as a Quantitative Myasthenia Gravis Score for disease severity (QMGS) of >10.5 and worsening weakness to IVIg (Gamunex®, Talecris Biotherapeutics) 1 g/kg/day for 2 consecutive days or PLEX (Caridian Spectra) 1.0 plasma volume exchanges for 5 exchanges. The patients were evaluated at day 14 after treatment for the primary efficacy parameter of change in QMGS and secondary clinical and electrophysiologic parameters and were followed for a total of 60 days. Results: Both IVIg and PLEX reduced the QMGS, and IVIg was comparable to PLEX in efficacy. The dropout rate was the same for both treatment arms and both treatments were well-tolerated. The presence of acetylcholine receptor antibodies and greater baseline disease severity predicted a better response to therapy. The postintervention status revealed that the same proportion of patients improved with treatment: 69% on IVIg and 65% on PLEX. The duration of improvement was similar with both treatments. Conclusions: IVIg has comparable efficacy to PLEX in the treatment of patients with moderate to severe MG. Both treatments are well-tolerated, and the duration of effect is comparable. Either treatment may be offered to patients depending on availability of resources. Classification of evidence: This study provides Class I evidence that IVIg and PLEX have comparable efficacy and are equally tolerated in adult patients with moderate to severe MG within 2 weeks of treatment.Keywords
This publication has 26 references indexed in Scilit:
- Evidence-based guideline update: Plasmapheresis in neurologic disordersNeurology, 2011
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- Disease‐specific measure of quality of life for myasthenia gravisMuscle & Nerve, 2008
- IVIG Treatment for Myasthenia GravisAnnals of the New York Academy of Sciences, 2008
- A Comparison of the Effectiveness of Intravenous Immunoglobulin and Plasma Exchange as Preoperative Therapy of Myasthenia GravisJournal of Clinical Neuromuscular Disease, 2008
- IV immunoglobulin in patients with myasthenia gravisNeurology, 2007
- Clinical evaluation and management of myasthenia gravisMuscle & Nerve, 2004
- Antibodies in Myasthenia Gravis and Related DisordersAnnals of the New York Academy of Sciences, 2003
- Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravisMuscle & Nerve, 2002
- Reliability Testing of the Quantitative Myasthenia Gravis ScoreaAnnals of the New York Academy of Sciences, 1998